Abstracts (HTML) List of Authors

Lahaye, M

Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial
Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy

Laimer, M

The natural course of anti-mitochondrial antibody positive subjects is similar in confirmatory immunoblot-M2 positive and negative subjects

Lamina, C

Penetrance, cancer incidence and survival of hemochromatosis in a long-term follow-up and epidemiological modeling study

Lang, T

Achieving hepatitis C elimination in people who inject drugs - interim results of an innovative screen-and-treat program in Austria
“Let’s end hepatitis C in Vienna” - the first HCV elimination program targeting homeless and people without medical insurance in Vienna
Directly observed therapy for hepatitis C with sofosbuvir/velpatasvir alongside opioid substitution as an effective micro elimination strategy in PWIDs at high risk of non-adherence to antiviral therapy - real world data from Vienna, Austria

Lange-Asschenfeldt, B

Elevation of liver enzyme under immunotherapy with checkpoint inhibitors

Längle, J

Der NAD+ salvage pathway in NK-Zellen bei intestinaler Inflammation

Le Bars, M

Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial
Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy

Leber, B

Die Auswirkungen eines multispezies-Synbiotikums auf Mikrobiom-assoziierte Nebenwirkungen einer Langzeit-Protonen-Pumpen-Hemmer Therapie: Eine Pilotstudie
Dysbiosis in dementia is associated with gut barrier dysfunction and linked to malnutrition and prescription drug use
Increased resting respiratory burst and decreased phagocytosis and chemotaxis: how bile acids impair neutrophil response in liver cirrhosis

Lens, S

SVR to DAA does not affect the risk of portal vein thrombosis in patients with advanced chronic liver disease

Leong, W

Corticosteroid Sparing Effects of Ustekinumab Therapy for Ulcerative Colitis Through 2 Years: UNIFI Long-term Extension

Lesnik, G

Factors associated with the presence of cirrhotic cardiomyopathy defined according to the new Multidisciplinary Diagnostic Criteria

Li, N

Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy

Liberman, A

Durable Response in the Markers of Cholestasis Through 5 Years of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis

Lim, H

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

Lin, C

Pregnancy Outcomes in Women with Psoriasis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis Treated with Ustekinumab

Ling, K

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

Llovet, J

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

Löwenberg, M

Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial

Ludwiczek, O

The need for psychological and psychotherapeutic interventions in Austrian patients with inflammatory bowel disease

Lukas, M

Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial